Skip to main content

Table 2 Drug treatment by class (overall study population and according to presence/absence of CKD)

From: Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases

 

Total T2DM

T2DM + CKDa

T2DM − CKDa

p-value

(n = 343,675)

(n = 171,930)

(n = 171,745)

Antidiabetic drugs

 Metformin in %

37.9

28.6

47.2

< 0.001

 Sulfonylurea in %

11.4

11.2

11.7

< 0.001

 Alpha-glucosidase inhibitors in %

1.2

1.3

1.1

< 0.001

 DPP-4 inhibitors in %

14.7

14.5

14.9

0.004

 Glinides in %

3.5

3.9

3.0

< 0.001

 SGLT-2 inhibitors in %

2.6

2.0

3.2

< 0.001

 GLP-1 RA in %

3.0

2.4

3.6

< 0.001

 Glitazones in %

1.1

1.0

1.2

< 0.001

 Short-acting insulin in %

44.0

51.4

36.7

< 0.001

 Long-acting insulin in %

46.3

53.5

39.1

< 0.001

 ≥ 2 antidiabetic drugs in %

18.0

15.0

21.0

< 0.001

Antihypertensive drugs

 Angiotensin converting enzyme inhibitors in %

31.2

33.8

28.6

< 0.001

 Angiotensin receptor blockers in %

12.3

14.2

10.3

< 0.001

 Beta-blockers in %

31.3

36.7

25.8

< 0.001

 Calcium channel blockers in %

16.2

19.5

12.9

< 0.001

 Diuretics in %

31.6

40.2

23.1

< 0.001

 ≥ 2 antihypertensive drugs in %

39.9

47.3

32.5

< 0.001

  1. Percent (%)
  2. CKD chronic kidney disease, DPP-4 dipeptidyl peptidase-4, GLP-1 RA glucagon-like peptide-1 receptor agonist, SGLT-2 sodium–glucose co-transporter-2, T2DM type 2 diabetes mellitus
  3. aDefined as eGFR < 60 mL/min/1.73 m2 OR eGFR ≥ 60 mL/min/1.73 m2 and albuminuria (≥ 30 mg/g)